Axitinib intermediate 886230-75-7
886230-75-7
Pharmaceutical Grade
99%
Xinke
foil bag
Yes
2022-02-15
Tenofovir alafenamide intermediate,Axitinib,Avatrombopag intermediate,Tenofovir alafenamide hemifumarate,Axitinib intermediate,Lenvatinib intermediate
-
Product Details
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
6-Nitro-3-[(1E)-2-(2-pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
Other Name:1H-Indazole,6-nitro-3-[(1E)-2-(2-pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-;6-Nitro-3-[(1E)-2-(2-pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole;(E)-6-Nitro-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
CAS No.:886230-75-7
Molecular Formula:C19H18N4O3
InChIKeys:InChIKey=BKXMYFOISYYOLE-JXMROGBWNA-N
Molecular Weight:350.37
Exact Mass:350.37
EC Number:1592732-453-0
HScode:2934999090
Categories:
Characteristics-
PSA:
85.76000
XLogP3:3.32
Density:1.4±0.1 g/cm3
Boiling Point:570.9±50.0 °C at 760 mmHg
Flash Point:299.1±30.1 °C
Refractive Index:1.681
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tenofovir alafenamide intermediate,Axitinib,Avatrombopag intermediate,Tenofovir alafenamide hemifumarate,Axitinib intermediate,Lenvatinib intermediate
-
Location:
No.108-102,Xinmao Qilu Science city,, Tianqiao district, Jinan City,
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
300 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2015
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
-
Lenvatinib Mesylate 99% 857890-39-2
Pharmaceutical Grade / 99%
-
-
-
-
Tenofovir alafenamide hemifumarate intermediate 99% 379270-37-8
Pharmaceutical Grade / 99%
-
-
-
-
Lenvatinib free base 417716-92-8
Pharmaceutical Grade / 99%
-
-
-
-
Lenvatinib Intermediate 17609-80-2
Pharmaceutical Grade / 98%
-
-
-
-
Tenofovir alafenamide hemifumarate 99% 1392275-56-7 Xinke
Pharmaceutical Grade / 99%
-
-
-
-
Axitinib 99% white to tan 319460-85-0
Pharmaceutical Grade / 99%
-